Correction to: Leukemia
Following the publication of this article, the authors noted minor errors in Supplementary Fig. 5. The correct version of this figure is included below along with the accompanying figure legend.
(A, B) Proliferation studies; 3-day LY3214996 treatment (A) or 6-day treatment (B) of primary AML patient samples. (C, D) Proliferation studies; 3-day LY3214996 treatment (C) or 6-day treatment (D) of normal PBMCs versus human AML cells. (E) LY3214996 treatment of AML patient sample 14 for 3 days. (F-G) Proliferation studies; 3-day LY3214996 or AZD6244 treatment of AML patient samples 12 (F) and 13 (G). Patient and primagraft information for all samples shown in this manuscript is provided in Supplementary Tables 1 and 2.
Author information
Authors and Affiliations
Corresponding authors
Additional information
The original article can be found online at https://doi.org/10.1038/s41375-019-0552-3.
Rights and permissions
About this article
Cite this article
Weisberg, E., Meng, C., Case, A. et al. Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia 34, 2543 (2020). https://doi.org/10.1038/s41375-020-0782-4
Published:
Issue date:
DOI: https://doi.org/10.1038/s41375-020-0782-4
